Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
February 26, 2024 08:00 ET
|
Orchestra BioMed Holdings, Inc.
8.9 mmHg mean reduction in 24-Hour ambulatory systolic blood pressure at average of 3.6 years from initiation of AVIM therapy in patients who participated in the MODERATO II study Orchestra BioMed is...
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 16:21 ET
|
Orchestra BioMed Holdings, Inc.
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patientsBACKBEAT pivotal...
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
September 19, 2023 07:30 ET
|
Orchestra BioMed Holdings, Inc.
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an...
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 16:34 ET
|
Orchestra BioMed Holdings, Inc.
U.S. Food and Drug Administration (“FDA”) granted Investigational Device Exemption (“IDE”) approval with conditions for Virtue SAB® coronary in-stent restenosis (“ISR”) U.S. pivotal study (in...
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
August 08, 2023 08:30 ET
|
Orchestra BioMed Holdings, Inc.
Virtue® Sirolimus AngioInfusion Balloon (“SAB”) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US...
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
June 26, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
June 07, 2023 08:30 ET
|
Orchestra BioMed Holdings, Inc.
Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly...
Orchestra BioMed to Present at the Jefferies Global Healthcare Conference
June 01, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update
May 12, 2023 09:15 ET
|
Orchestra BioMed Holdings, Inc.
Completed business combination and listing on Nasdaq generating gross proceeds of approximately $70 millionBackBeat CNT™ global pivotal study in hypertensive pacemaker patients on track for initiation...
Orchestra BioMed to Present at Upcoming Investor Conferences
March 07, 2023 08:00 ET
|
Orchestra BioMed Holdings, Inc.
NEW HOPE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to...